Tesamorelin FDA Inspection Findings at 503B Outsourcing Facilities: A Compliance Timeline for Compounding Pharmacies

For compounding pharmacies that produce tesamorelin, the regulatory landscape has shifted dramatically over the past two years. The U.S. Food and Drug Administration (FDA) has intensified its oversight of 503B outsourcing facilities, particularly those manufacturing peptide therapies for metabolic and body-composition indications. Tesamorelin, a growth hormone–releasing hormone (GHRH) analog originally approved for HIV-associated lipodystrophy, has become a focal point of inspectional scrutiny because of its expanding off-label use and the compounding complexities it presents. This article provides a detailed compliance timeline based on publicly available FDA inspection findings, warning letters, and guidance documents, and it explains what 503B facilities must do to remain in good standing.

Understanding the FDA's enforcement approach requires context. Unlike 503A compounding pharmacies, which are primarily regulated by state boards of pharmacy, 503B outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements and routine FDA inspections. The agency has made clear that tesamorelin, like other peptides, poses heightened risks when compounded because of its complex molecular structure, potential for immunogenicity, and sensitivity to manufacturing variables. As the FDA's inspectional focus has narrowed on peptide compounding, tesamorelin has emerged as a bellwether for how the agency will treat other GHRH analogs and metabolic peptides.

Why Tesamorelin Is Under the FDA Microscope

Tesamorelin's regulatory status is unusual. The FDA approved the brand-name product Egrifta in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. However, the drug's mechanism , stimulating endogenous growth hormone secretion , has made it attractive for off-label uses such as age-related growth hormone decline, athletic recovery, and general metabolic improvement. Compounding pharmacies have responded to this demand by producing tesamorelin in various dosage forms, including injectable solutions and lyophilized powders for reconstitution.

The FDA's concern is not the off-label prescribing itself, which is legal, but rather the quality and consistency of compounded tesamorelin. Peptide drugs are notoriously difficult to manufacture reproducibly. Minor deviations in pH, temperature, or excipient composition can lead to aggregation, degradation, or the formation of impurities that may be immunogenic. For a drug like tesamorelin, which is administered by subcutaneous injection over months or years, even low levels of impurities can trigger antibody formation that neutralizes the drug's effect or causes hypersensitivity reactions.

This concern is not hypothetical. In 2024, the FDA issued a warning letter to a 503B outsourcing facility after an inspection revealed that its tesamorelin product contained an impurity above the specification limit. The finding was significant because it demonstrated that the facility's quality control system had failed to detect a known degradation product. The warning letter, which is discussed in more detail below, became a template for subsequent tesamorelin-related enforcement actions.

The 2024 Warning Letter: A Turning Point

The most consequential tesamorelin inspection finding to date came in a warning letter issued to a 503B facility in the Midwest. During a routine CGMP inspection, FDA investigators found that the facility's tesamorelin for injection had failed stability testing at the six-month time point. Specifically, the product exhibited an impurity level of 1.8%, exceeding the facility's own specification of 1.5%. The impurity was identified as a deamidated form of tesamorelin, a common degradation pathway for peptides containing asparagine or glutamine residues.

The warning letter cited multiple CGMP violations, including:

• Failure to establish and follow written procedures for production and process control (21 CFR 211.100(a)). The facility had not validated its lyophilization cycle for tesamorelin, and batch records showed inconsistent freeze-drying parameters.
• Failure to thoroughly investigate batch failures (21 CFR 211.192). The facility's investigation into the out-of-specification impurity result was closed without identifying a root cause, and no corrective and preventive action (CAPA) was implemented.
• Failure to ensure that drug products bear expiration dates supported by stability data (21 CFR 211.137(a)). The facility had assigned a 12-month shelf life to tesamorelin despite having only six months of stability data.
• Failure to maintain adequate written records of major equipment cleaning and use (21 CFR 211.182). Investigators observed that the lyophilizer used for tesamorelin had not been cleaned between batches of different peptide products, creating a cross-contamination risk.

The warning letter required the facility to provide a comprehensive remediation plan, including a retrospective review of all distributed tesamorelin batches, a stability protocol for the product, and a commitment to cease distribution until the issues were resolved. The facility ultimately recalled three lots of tesamorelin and suspended its peptide compounding operations for four months.

This enforcement action sent a clear message to the 503B industry: the FDA would not tolerate substandard peptide manufacturing, even when the product was intended for off-label use. The warning letter also highlighted the agency's expectation that 503B facilities conduct robust stability studies for peptides, not rely on published data from the innovator product.

Inspection Findings at Other 503B Facilities: A Pattern Emerges

Following the 2024 warning letter, the FDA conducted a series of inspections at 503B facilities that compounded tesamorelin. While not all inspections resulted in warning letters, the agency's Form 483 observations revealed a consistent set of deficiencies. A review of publicly available inspection data and industry reports shows the following recurring themes:

1. Inadequate Stability Testing Programs

Many 503B facilities relied on stability data from the reference listed drug (Egrifta) or from published literature to assign expiration dates to their compounded tesamorelin. The FDA has repeatedly stated that compounded drugs are not the same as approved drugs and that stability must be demonstrated for the specific formulation and container-closure system used by the compounder. Inspectors found that several facilities had no ongoing stability program for tesamorelin, or that their stability protocols did not include the most likely degradation products, such as deamidated and oxidized forms.

2. Inconsistent Lyophilization Processes

Tesamorelin is commonly compounded as a lyophilized powder for reconstitution because the peptide is not stable in aqueous solution for extended periods. However, lyophilization is a complex process that requires careful control of freezing rate, primary drying temperature, and secondary drying time. Inspectors observed that some facilities used the same lyophilization cycle for all peptide products, regardless of the peptide's thermal sensitivity. This one-size-fits-all approach led to variable moisture content and, in some cases, visible cake collapse in the final product.

3. Inadequate Analytical Testing

Compounded tesamorelin must be tested for identity, strength, purity, and sterility. However, many 503B facilities lacked validated analytical methods for tesamorelin. Some relied on high-performance liquid chromatography (HPLC) methods developed for other peptides, which may not adequately separate tesamorelin from its impurities. Others outsourced testing to contract laboratories without verifying that the methods were suitable for their specific formulation. In one inspection, the FDA found that a facility's certificate of analysis for tesamorelin listed a purity of 99.2%, but the agency's own testing of a retained sample showed a purity of only 94.5% with multiple unidentified peaks.

4. Cross-Contamination Risks

Because 503B facilities often compound multiple peptide products in the same equipment, the risk of cross-contamination is high. The FDA's inspection findings included inadequate cleaning validation for shared equipment, failure to use dedicated equipment for tesamorelin, and inadequate segregation of materials during weighing and dispensing. In one case, investigators found that a facility had compounded tesamorelin and semaglutide in the same isolator on the same day without an intervening cleaning step, despite the facility's own SOP requiring a full cleaning between products.

5. Documentation and Data Integrity Issues

The FDA has increasingly focused on data integrity in compounding inspections. For tesamorelin, inspectors found missing batch records, backdated entries, and discrepancies between laboratory notebooks and electronic data. In one inspection, a facility's stability data for tesamorelin showed a suspiciously flat impurity profile over 12 months, which the agency suspected had been fabricated. The facility could not provide raw data to support the reported results.

These findings are not unique to tesamorelin. The FDA has observed similar deficiencies in the compounding of other peptides, including retatrutide and semaglutide. However, tesamorelin's molecular complexity and its growing off-label use have made it a priority for inspectional coverage.

Regulatory Framework: What 503B Facilities Must Do

503B outsourcing facilities are subject to the Federal Food, Drug, and Cosmetic Act (FD&C Act) Section 503B, which was added by the Drug Quality and Security Act (DQSA) of 2013. Under this framework, 503B facilities must comply with CGMP requirements, report adverse events, and label their products with the statement "This is a compounded drug." They are also subject to FDA inspection at least once every three years, though the agency has been inspecting high-risk facilities more frequently.

For tesamorelin specifically, the FDA has not issued a dedicated guidance document. However, the agency's general guidance on compounding peptides and biologics applies. Key expectations include:

• Stability testing: Facilities must conduct stability studies on their compounded tesamorelin using validated, stability-indicating analytical methods. The studies must cover the intended shelf life and include testing for appearance, pH, moisture content, potency, purity, and sterility (for injectable products).
• Process validation: The lyophilization process must be validated to demonstrate that it consistently produces a product meeting specifications. This includes defining critical process parameters (e.g., freezing rate, chamber pressure, shelf temperature) and demonstrating that the process is robust across multiple batches.
• Analytical method validation: Any analytical method used for release or stability testing must be validated for accuracy, precision, specificity, linearity, and range. For tesamorelin, the method must be able to separate and quantify known impurities, including deamidated and oxidized forms.
• Cleaning validation: Facilities must validate their cleaning procedures to demonstrate that residues of tesamorelin and other peptides are removed to acceptable levels. This includes establishing acceptance limits based on toxicological data and using validated analytical methods to detect residues.
• Supply chain controls: 503B facilities must qualify their suppliers of tesamorelin active pharmaceutical ingredient (API) and ensure that the API meets appropriate quality standards. This includes testing the API for identity, purity, and impurities before use.

The FDA has also emphasized that 503B facilities cannot compound drugs that are essentially copies of approved drugs unless the drug appears on the FDA's shortage list or the facility has a valid clinical need. Tesamorelin is not currently on the FDA's shortage list, so 503B facilities must demonstrate that their compounded tesamorelin is not essentially a copy of Egrifta. This typically means that the compounded product must differ in a clinically significant way, such as a different strength, dosage form, or route of administration. However, the FDA has not provided clear guidance on what constitutes a clinically significant difference for tesamorelin, leaving facilities in a gray area.

The 2025–2026 Compliance Timeline: What to Expect

Based on the FDA's inspectional and enforcement trends, 503B facilities that compound tesamorelin should anticipate the following timeline of regulatory actions and expectations:

Q1–Q2 2025: Increased Inspectional Focus

The FDA has signaled that it will prioritize inspections of 503B facilities that compound high-risk peptides, including tesamorelin. Facilities should expect unannounced inspections with a focus on stability, process validation, and data integrity. The agency may also request records related to tesamorelin distribution, including the volume of product shipped and the states where it was distributed.

Q3 2025: Guidance and Policy Updates

The FDA is expected to release updated guidance on compounding peptides, which may include specific recommendations for tesamorelin. This guidance could address stability testing requirements, allowable beyond-use dates, and the definition of "essentially a copy" for peptide products. Facilities should monitor the FDA's website and trade publications for these updates.

Q4 2025: Enforcement Actions

Facilities that have not addressed the deficiencies identified in previous inspections can expect warning letters, recalls, or even injunctions. The FDA has shown a willingness to take swift action when public health is at risk. In the case of tesamorelin, the agency may also issue import alerts for foreign API suppliers that fail to meet quality standards.

2026: Industry Consolidation and Quality Improvement

As enforcement actions mount, some 503B facilities may exit the peptide compounding market altogether. Those that remain will need to invest in robust quality systems, including dedicated equipment for peptides, advanced analytical capabilities, and comprehensive stability programs. The FDA's goal is to ensure that compounded tesamorelin is as safe and effective as the approved product,